PrimeRFP SCOUT · Federal Contract Recompete Brief

36C25926F0001Galafold 123 MG capsule - NTE — Amicus Therapeutics Us, LLC

Amicus Therapeutics Us, LLC holds $3.4M across 74 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79724D0185. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Nov 14, 2026 PoP end — agencies typically plan 12–18 months ahead.

Network Contract Office 19 (36C259)

Awarding office

Amicus Therapeutics Us, LLC

Recipient

Nov 14, 2026

PoP end

$295K

Obligated

$295K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amicus Therapeutics Us, LLC — $90

Contract facts

Federal

Contract number36C25926F0001

Also listed as36C259-26-F-0001

Also listed as36F79724D0185-36C25926F0001

AgencyNetwork Contract Office 19 (36C259)

Awarding officeNetwork Contract Office 19 (36C259)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentAmicus Therapeutics Us, LLC

CAGE867U3

UEIKLJFGENKMD89

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79724D0185

Place of performancePHILADELPHIA PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startNov 15, 2025

PoP end (current)Nov 14, 2026

Obligated$295K

Current value$295K

Potential value$295K

GALAFOLD 123 MG CAPSULE - NTE is a federal award for Network Contract Office 19 (36C259) held by Amicus Therapeutics Us, LLC. Estimated value $295K ($295K obligated). Current period of performance ends Nov 14, 2026. Last award drew 1 bidder. Place of performance: PHILADELPHIA PA.

Recompete timing

Public

● Expiring in 85 days

Current PoP ends Nov 14, 2026 (85 days remaining). Agencies typically plan 12–18 months ahead — at 2.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Amicus Therapeutics Us, LLC — $3.4M obligated across 74 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$3.4M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C24726F0100

GALAFOLD MEDICATION

$228K

Feb 22, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C25926F0001?

36C25926F0001 (Galafold 123 MG capsule - NTE) is a Network Contract Office 19 (36C259) award with a potential value of $295K, currently held by Amicus Therapeutics Us, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C259-26-F-0001?

36C259-26-F-0001 is the dashed form of PIID 36C25926F0001 (Galafold 123 MG capsule - NTE), held by Amicus Therapeutics Us, LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C25926F0001?

Network Contract Office 19 (36C259) awarded 36C25926F0001 to Amicus Therapeutics Us, LLC (potential $295K).

Who is the incumbent on 36C25926F0001?

Amicus Therapeutics Us, LLC is the incumbent with $3.4M across 74 related awards in SCOUT’s public footprint. The current period of performance ends Nov 14, 2026.

When does Amicus Therapeutics Us, LLC’s 36C25926F0001 come up for recompete?

SCOUT tracks a period-of-performance end of Nov 14, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 25, 2026 · refreshed monthlyLatest procurement action Jan 30, 2026